Evidence-based symptom relief of intermittent claudication: Efficacy and safety of cilostazol

Diabetes, Obesity and Metabolism

Volumn 4, Issue SUPPL. 2, 2002, Pages

  Donnelly, Richard ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cilostazol; Functional outcome; Intermittent claudication; Phosphodiesterase III inhibitor; Symptomatic relief

Indexed keywords

CILOSTAZOL; PENTOXIFYLLINE; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

CLAUDICATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDEMA; EVIDENCE BASED MEDICINE; HEADACHE; HEART PALPITATION; HUMAN; QUALITY OF LIFE; REVIEW; TACHYCARDIA; UNITED KINGDOM; EXERCISE; INTERMITTENT CLAUDICATION; SAFETY; STANDARD;

CLINICAL TRIALS; EXERCISE; HUMANS; INTERMITTENT CLAUDICATION; QUALITY OF LIFE; SAFETY; TETRAZOLES; VASODILATOR AGENTS;

EID: 0038111265     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2002.0040s2s20.x     Document Type: Review

References (24)

1. Boon NA, Fox K. Diseases of the cardiovascular system. In: Edwards, CRW et al, eds. Davidson's Principles and Practice of Medicine, 17th edn. Edinburgh: Churchill Livingstone, 1995: 191-312.
2. Fowkes FG, Housley E, Cawood EH et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-392.
3. Dormandy JA, Rutherford RB, for the TASC Working Group et al. Management of peripheral arterial disease. J Vasc Surg 2000; 31: S1-S296.
4. Weitz JI, Byrne J, Clagett P et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-3049.
5. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA 1995; 274: 975-980.
6. Krupski WC. The peripheral vascular consequences of smoking. Ann Vasc Surg 1991; 5: 291-304.
7. Money SR, Herd JA, Isaacsohn JL et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267-275.
8. Donnelly R. Assessment and management of intermittent claudication: importance of secondary prevention. Int J Clin Pract Supplement 2001; 119: 2-9.
9. Goldhaber SZ, Manson JE, Stampfer MJ et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physician's Health Study. Lancet 1992; 340: 143-145.
10. CAPRIE. Steering Committee. A randomised blinded trial of clopidogrel vs aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
11. Leng GC, Price JF, Jepson RG. Cochrane review: lipid-lowering therapy in the treatment of lower limb atherosclerosis. Eur J Vasc Endovasc Surg 1998; 16: 5-6.
12. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
13. Hiatt WR, Hirsch AT, Regensteiner JG et al. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end-points. Circulation 1995; 92: 614-621.
14. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530.
15. Dawson DL, DeMaioribus CA, Hagino RT et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999; 178: 141-146.
16. Gallus AS, Gleadow F, Dupont P et al. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust NZ J Med 1985; 15: 402-409.
17. Johnson WC, Watkins MT, Hamilton J et al. Pentoxifylline therapy for intermittent claudication: are patients dependent on therapy? Surgery 1994; 115: 735-739.
18. Scottish Intercollegiate Guidelines Network. Drug therapy for peripheral vascular disease. A national clinical guideline. SIGN publication number 27 1998.
19. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest 1998; 114: 666S-682S.
20. Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159: 337-345.
21. Cariski AT. Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Pract 2001; 119(Suppl.): 11-18.
22. Beebe HG, Dawson DL, Cutler BS et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159: 2041-2050.
23. Hiatt WR. New treatment options in intermittent claudication: the US experience. Int J Clin Pract 2001; 119(Suppl.): 18-25.
24. Ware JEJ. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center 1993.